Severity
Critical
FDA Drug recall · Reported April 24, 2024
Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
AvKARE recalled Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only… - a critical-severity action.
Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only… was recalled by AvKARE in April 24, 2024. Reason: Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.. Check the official notice for the remedy. Verify recall #D-0444-2024 with the FDA Drug before acting.
The recall
AvKARE issued this critical-severity FDA Drug recall-Microbial contamination of a non-sterile product: potential Bacillus cereus contamination..
Sourced from official FDA Drug enforcement records. Verify recall #D-0444-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0444-2024) was formally reported on April 24, 2024, with the manufacturer initiating the action on March 28, 2024. It is classified under Critical severity (Class I), with a current status of Terminated. AvKARE is listed as the recalling firm, operating out of Pulaski, TN. Federal records list the affected scope as 153 cartons.
The documented reason for this recall is: Microbial contamination of a non-sterile product: potential Bacillus cereus contamination. Distribution data in the federal record shows the product reached: US Nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
153 cartons
Related Recalls
6
5 from same agency
Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.
Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-0444-2024 |
| Date reported | April 24, 2024 |
| Date initiated | March 28, 2024 |
| Recalling firm | AvKARE |
| Firm location | Pulaski, TN |
| Affected scope | 153 cartons |
| Distribution | US Nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 24, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.